此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss (COPAN-ORL06)

2021年3月24日 更新者:UNICANCER

Phase ib/II Trial of Copanlisib, a Selective PI3K Inhibitor, in Combination With Cetuximab in Patients With Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC) Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss.

The study consists of two distinct and sequential parts:

  • A Phase Ib aimed at determining the MTD (Maximum Tolerated Dose) of the combination (copanlisib/cetuximab) and the RP2D
  • A Phase II aimed at evaluating the efficacy of the combination at the RP2D (Recommended Phase 2 Dose)

All patients will be treated with the Copanlisib, a selective PI3KCA inhibitor, in association with Cetuximab.

研究概览

研究类型

介入性

注册 (实际的)

11

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Angers、法国、49933
        • Institut de Cancérologie de l'Ouest
      • Dijon、法国、21079
        • Centre Georges François Leclerc
      • Lille、法国、59020
        • Centre Oscar Lambret
      • Lyon、法国、69437
        • Centre Léon Bérard
      • Nancy、法国、54511
        • Institut de Cancérologie de Lorraine
      • Nice、法国、06189
        • Centre Antoine Lacassagne
      • Paris、法国、75005
        • Institut Curie

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Patients with R/M HNSCC (oropharynx, oral cavity, hypopharynx and larynx), histologically or cytologically confirmed, not amenable to curative treatment with surgery and/or chemotherapy and/or radiotherapy (Stage III/IV)
  2. Adult men and women ≥ 18 years
  3. Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2
  4. Patients with tumor harboring a PI3K mutation/amplification and/or a PTEN loss
  5. Patients with a radiologic documented progression or relapse after cetuximab therapy (patients could have either received combination platinum doublet with cetuximab or cetuximab after platinum doublet)
  6. Patients with prior platinum based therapy, unless contraindicated
  7. Patients with at least one measurable lesion assessed by Magnetic Resonance Imaging (MRI) or a computerized tomography scanner (CT-scan) according to RECIST v1.1. Patients must have clinically and/or radiographically documented measurable disease. At least one site of disease must be unidimensionally measurable as follows

    • CT-scan, physical exam ≥ 10 mm
    • Lymph node short axis ≥ 15 mm Tumor measurements must be performed within 28 days prior to starting study drug
  8. Women of childbearing potential and men must agree to use adequate contraception when sexually active. This applies since signing of the informed consent form and up to 12 months (for women of child bearing potential) and 6 months (for fertile men) after the last study drug administration (Copanlisib). Highly effective contraception methods are detailed in section 7.2
  9. Women of childbearing age or sexually active female patients with reproductive potential must have a negative pregnancy test (serum or urine within the 7 days prior to starting study drug)
  10. Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses
  11. Patients with social insurance coverage
  12. Glomerular filtration rate (GFR) ≥ 40 mL/min/1.73 m² according to the Modification of Diet in Renal Disease (MDRD) abbreviated formula (within 7 days prior to starting study drug). If not on target, this evaluation may be repeated once after at least 24 hours either according to the MDRD abbreviated formula or by 24 hour sampling. If the later result is within acceptable range, it may be used to fulfill the inclusion criteria instead

Exclusion Criteria:

  1. Patients previously treated with PI3K and/or mTOR inhibitors
  2. Patients with anticancer therapy (radiotherapy, immunotherapy, chemotherapy, etc.) within 28 days or investigational treatment within 28 days prior to the initiation of study drug treatment, unless evidence of progression since last treatment
  3. Patients currently using other approved or investigational anti-neoplasic agent
  4. Patients with uncontrolled arterial hypertension despite optimal medical management, Congestive heart failure > New York Heart Association (NYHA) class 2, Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months). Myocardial infarction less than 6 months before start of test drug No active cardiac disease including any of the following: left ventricular ejection fraction (LVEF) < 50% as determined by Multiple Gated Acquisition (MUGA) scan or echocardiogram (ECHO) and QTc > 470 ms on screening ECG
  5. Patients with uncontrolled diabetes mellitus (patients with controlled Type I or II diabetes mellitus will be eligible but only into the phase II of the study and only if fasting HbA1c ≤ 8.5% at screening)
  6. Patients with a history of Human Immunodeficiency Virus (HIV) Hepatitis B (HBV) or hepatitis C (HCV) infection. All patients must be screened for HIV, HBV and HCV up to 28 days prior to first dosing using the routine virus laboratorial panel. Patients who are positive for HBs Ag or HBc Ab will be eligible if they are negative for HBV-DNA. Patients who are positive for anti-HCV antibody will be eligible if they are negative for HCV-RNA
  7. Patients with active uncontrolled or symptomatic central nervous system (CNS) metastases. Patients are eligible if their disease is controlled at least 30 days on corticosteroids prior to starting study drug
  8. Patients with major surgery within 28 days, or open biopsy within 7 days, prior to starting study drug. Patients must have recovered from major side effects of the surgery
  9. Patients receiving any medications or substances that are inhibitors or inducers of CYP3A4 are ineligible. Copanlisib is primarily metabolized by CYP3A4. Therefore concomitant use of strong inhibitors of CyP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir), and inducers of CYP3A (e.g. rifampin, phenytoin, carbamazepine, phenobarbital, st. John's Wort) are not permitted from Day -14 of Cycle 1 until the Safety follow up visit
  10. Patients with altered hematopoietic or organ function, as indicated by the following criteria (assessed within 7 days prior the first dosing):

    • Absolute granulocytes < 1.0 x 10⁹/L
    • Platelets < 75 x 10⁹/L
    • ALAT/ASAT > 2.5 x ULN in the absence of or > 5 x ULN in the presence of liver metastases
    • Bilirubin > 1.5 x ULN (except Gilbert Syndrome: < 3.0 mg/dL)
    • Creatinine clearance < 60 mL/min (measured or calculated by Cockcroft and Gault formula) or serum creatinine > 1.0 x ULN
    • Lipase > 1.5 x ULN
    • INR and PTT > 1.5 x ULN
  11. Patients with a history of hypersensitivity to other monoclonal antibodies or to the active or inactive excipients of study drug
  12. Known drug or alcohol abuse
  13. Known or underlying medical condition that, in the investigator's opinion, would make the administration of study drug hazardous to the patient or obscure the interpretation of toxicity determination or adverse events
  14. History of uncontrolled seizures, seizure disorder requiring medication, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake
  15. Unwillingness to give written informed consent, unwillingness to participate, or inability to comply with the protocol for the duration of the study
  16. Individuals deprived of liberty or placed under the authority of a tutor
  17. Previous or concurrent history of malignancies within 5 years prior to study treatment except for curatively treated:

    • Cervical carcinoma in situ
    • Non-melanoma skin cancer
    • Superficial bladder cancer (Ta [non-invasive tumor], Tis [carcinoma in situ] and T1 [tumor invades lamina propria])
    • Localized prostate cancer
  18. Patients with evidence or history of bleeding diathesis. Any hemorrhage or bleeding event ≥ CTCAE Grade 3 within 4 weeks prior to the start of study medication
  19. Proteinuria of ≥ CTCAE Grade 3 as assessed by a 24h protein quantification or estimated by urine protein-creatinine ratio > 3.5 on a random urine sample
  20. History or concurrent condition of interstitial lung disease of any severity and/or severely impaired lung function (as judged by the investigator)
  21. Concurrent diagnosis of pheochromocytoma
  22. Pregnant or breast-feeding patients. Women of childbearing potential must have a serum pregnancy test performed a maximum of 7 days before start of treatment, and a negative result must be documented before start of treatment
  23. Unresolved toxicity higher than CTCAE Grade 1 attributed to any prior therapy/procedure, excluding alopecia
  24. Ongoing immunosuppressive therapy
  25. Blood or platelets transfusion less than 7 days before starting treatment
  26. Myeloid growth factors within 14 days prior to treatment
  27. Systemic continuous corticosteroid therapy at a daily dose higher than 15 mg prednisone or equivalent is not allowed. Previous corticosteroid therapy must be stopped or reduced to the allowed dose 7 days before performing the screening CT scan/MRI, whichever is performed first, and again prior to the first study drug administration. If a patient is on chronic corticosteroid therapy, corticosteroids should be de-escalated to the maximum allowed dose after the patient has signed the IC. Patients may be using topical or inhaled corticosteroids
  28. History of having received an allogeneic bone marrow or organ transplant
  29. Anti-arrhythmic therapy (beta blockers or digoxin are permitted)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Copanlisib + Cetuximab
All patients will be treated by Copanlisib in association with Cetuximab.
Copanlisib will be given at Day 1, Day 8 and Day 15 (1 cycle = 28 days), administered intravenously over 60 minutes, in association with Cetuximab.
其他名称:
  • 海湾 80-6946
Cetuximab will be given weekly at Day 1, Day 8, Day 15 and Day 22 (1 cycle = 28 days), administered intravenously over 120 minutes (Cycle 1 Day 1) or 60 minutes (subsequent infusions), in association with Copanlisib.
其他名称:
  • 爱必妥

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Phase Ib (dose escalation phase): to determine the Maximal Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of Copanlisib in association with Cetuximab
大体时间:1 month
Determination of the MTD will be based on the occurence of Dose Limiting Toxicities during Cycle 1.
1 month
Phase II (expansion phase) : to assess the efficacy of the combination (Copanlisib + Cetuximab) at the RP2D.
大体时间:16 weeks
Efficacy of the combination will be assessed through Progression Free Survival at week 16.
16 weeks

次要结果测量

结果测量
措施说明
大体时间
Efficacy of the combination
大体时间:Through the study completion with an average of 10 months
Objective Response Rate (ORR) using RECIST 1.1 criteria
Through the study completion with an average of 10 months
Efficacy of the combination
大体时间:Through the study completion with an average of 10 months
Overall Survival (OS)
Through the study completion with an average of 10 months
Adverse Events (NCI CTCAE v4.0)
大体时间:Up to 15 cycles
All Adverse Events (NCI CTCAE v4.0), related or not related to Copanlisib or Cetuximab, will be collected in the Case Report Form in order to picture the safety profile of the association.
Up to 15 cycles
Copanlisib Maximum Plasma Concentration [Cmax]
大体时间:First Month (at Day 1 and Day 15)
For patients enrolled in the phase Ib (dose escalation phase) pharmacokinetic samples (blood) will be collected at Cycle 1 Day 1 and Cycle 1 Day 15. There will be 5 samples per day: pre-infusion, end of infusion, 2 hours, 8 hours and 24 hours after the start of Copanlisib infusion.
First Month (at Day 1 and Day 15)
Area Under the Curve [AUC] for Copanlisib pharmacokinetic
大体时间:First Month (at Day 1 and Day 15)
For patients enrolled in the phase Ib (dose escalation phase) pharmacokinetic samples (blood) will be collected at Cycle 1 Day 1 and Cycle 1 Day 15. There will be 5 samples per day: pre-infusion, end of infusion, 2 hours, 8 hours and 24 hours after the start of Copanlisib infusion.
First Month (at Day 1 and Day 15)
Mutational profile of circulating tumoral DNA (ctDNA)
大体时间:through the study duration: baseline, C1D1, C1D15, 8 weeks, disease progression
For patients enrolled in the phase II (dose escalation phase) blood samples will be collected at baseline, C1D1, C1D15, 8 weeks, Disease progression or end of treatment whichever comes first.
through the study duration: baseline, C1D1, C1D15, 8 weeks, disease progression

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2016年6月1日

初级完成 (实际的)

2019年10月9日

研究完成 (实际的)

2019年10月9日

研究注册日期

首次提交

2016年6月16日

首先提交符合 QC 标准的

2016年6月29日

首次发布 (估计)

2016年7月4日

研究记录更新

最后更新发布 (实际的)

2021年3月29日

上次提交的符合 QC 标准的更新

2021年3月24日

最后验证

2021年3月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual Participant Data will not be shared at an individual level. Those data will be part of the study database including all enrolled patients.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅